Positive Results, Exclusive Agreements, and Orphan Drug Designations - Research Report on Bristol-Myers Squibb, Illumina, Alexion, Health Net, and Emeritus Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, July 8, 2013 NEW YORK, July 8, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Illumina, Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Health Net, Inc. (NYSE: HNT), and Emeritus Corporation (NYSE: ESC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Bristol-Myers Squibb Company Research Report On June 30, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and Pfizer Inc. (Pfizer) jointly announced the results of the six month Phase 3 AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE). The Companies reported that Eliquis as a single-agent achieved the primary efficacy endpoint of noninferiority to current standard of care (initial parenteral enoxaparin treatment overlapped with warfarin therapy) in the reduction of the composite endpoint of recurrent symptomatic VTE or VTE-related death. Both the Companies now plan to initiate regulatory filings for the initial and long-term treatment of VTE, and for extended prevention of recurrent VTE. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/88a2_BMY] -- Illumina, Inc. Research Report On July 1, 2013, Illumina, Inc. (Illumina) announced that Teva Pharmaceutical Industries Ltd. (Teva) has signed an exclusive agreement with Verinata Health (Verinata), a wholly-owned subsidiary of Illumina, for the commercialization of the verifi non-invasive prenatal test in Israel. Under the terms of the five-year agreement, Teva will be the exclusive distributor of the verifi prenatal test in Israel, and all tests will be run in Verinata's CLIA-certified (Clinical Laboratory Improvement Amendments) laboratory in California. According to Illumina, the MOR Institute for Medical Data Ltd. (MOR Institute), through its relationship with Teva, will provide the verifi prenatal test to customers of Clalit Health Services who are at high risk of having a fetus with chromosomal abnormality. Illumina also reported that MOR Institute, which is a wholly-owned subsidiary of Clalit Health Services, will also establish a 9000-patient clinical outcomes registry to collect performance data and will share it with Verinata. Clalit Health Services will reimburse for the verifi prenatal test through supplemental insurance. The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/3af7_ILMN] -- Alexion Pharmaceuticals, Inc. Research Report On June 27, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that Soliris (eculizumab), the Company's first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of neuromyelitis optica (NMO) - a life-threatening, ultra-rare neurological disorder. Martin Mackay, Ph.D., EVP and Global Head of R&D at Alexion, said, "This orphan drug designation is a positive step toward understanding and meeting the needs of this underserved patient population. In clinical trials to date, terminal complement inhibition with Soliris appeared to significantly reduce the attack rate in patients with severe, refractory relapsing NMO." According to Alexion, the Orphan drug designation provides a drug developer with certain benefits and incentives (including a period of marketing exclusivity) if regulatory approval is received for the designated indication. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/451f_ALXN] -- Health Net, Inc. Research Report On July 2, 2013, Health Net of California, Inc., a wholly-owned subsidiary of Health Net, Inc. (Health Net), announced that on May 3, 2013, the Company became aware that California member identification cards of some of the members were inadvertently mailed to their former addresses in April and May 2013. According to the Company, the mailing was part of a program transition of Health Net members to the Health Net Medi-Cal program, and the Company has been investigating the issue as well as working with the California Department of Health Care Services (DHCS) on this matter. The Company also informed that the programming issue responsible for this action has been addressed, and confirmed that it is in the process of notifying affected members that the information sent to their former addresses included their plan identification number. Health Net also reported that it has notified the appropriate governmental authorities within the required time frames. The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/6f92_HNT] -- Emeritus Corporation Research Report On June 27, 2013, Emeritus Corporation (Emeritus) announced that it has entered into definitive agreements with Health Care REIT, Inc. (HCN) and Merill Gardens. Under the agreements, the Company will lease a total of 38 senior housing communities in eight states, representing approximately 4,400 units, which are currently owned by a joint venture comprised of HCN and Merill Gardens. Upon consummation of the transaction, HCN will acquire Merill Gardens' 20% equity interest in the property and Emeritus will operate it under a long-term triple-net master lease. Rent for the first year will be $54 million and will increase each year in the manner specified in the lease. The initial term of the lease will be 15 years, along with an option with Emeritus to extend it for an additional term of 15 years. The transaction, subject to customary closing conditions, is expected to close in beginning of August 2013. The Full Research Report on Emeritus Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/df13_ESC] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Positive Results, Exclusive Agreements, and Orphan Drug Designations - Research Report on Bristol-Myers Squibb, Illumina,
Press spacebar to pause and continue. Press esc to stop.